The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Clinical Applications of ctDNA in Breast Cancer Diagnosis and Manage…

University of Miami Sylvester Comprehensive Cancer Center

D. Tripathy

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cance…

2024 ESMO Annual Meeting Insights Hub

S. Ogino

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

Visible vs. Invisible Cancers - The Genomics and Natural History

Laurence Klotz

ESMO 2024 Summary: Metastatic Melanoma Highlights

2024 ESMO Annual Meeting Insights Hub

C. Blank

Cancer Genomics: Molecular Profile Interpretation 101

Total Health

L. Welch

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez